TG Therapeutics, Inc. (NASDAQ:TGTX) today participated in the 36th Annual J.P Morgan Healthcare Conference in San Francisco and as a result, the stock has increased by almost 15%.
TG Therapeutics is a biopharmaceutical company engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. At the moment, TG Therapeutics is working on two therapies, ublituximab and umbralisib, to target hematological malignancies and autoimmune diseases. Both therapies are currently in Phase III of the clinical development stage.
The Executive Chairman and Chief Executive Officer for TG Therapeutics, Michael S. Weiss, took charge of the presentation, which occurred earlier in the day at 7:30 am PST. To listen to a webcast of the presentation, visit the Events page on the TG Therapeutics website.
The overall response to the presentation at the J.P Morgan Healthcare Conference was positive, which shows in TG Therapeutics’ stock increase for the day. At the time of writing, the stock is trading at $10.57 on the Nasdaq Capital Market Exchange, putting the stock’s price up $1.37, or 14.89%, from the previous closing price of $9.20. The stock opened this morning at $9.30. So far, the day’s pricing has ranged from the opening price of $9.30 and $10.74. Today’s high of $10.74 is the highest the stock has been in the past four weeks; however the 52-week range, which goes from $4.10 to $15.35, indicates that the stock has performed better this last year than it is currently doing, despite the growth it has seen in the last four weeks. Currently, TG Therapeutics has a market cap of $746.795 million.
The presentation today was a good start for TG Therapeutics in beginning a stock recovery, but there is still a long way to go. The good news is that the stock is already doing better than it was a year ago, at $4.95 on January 11, 2017.
Featured Image: twitter
